Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 13/20 | 0.48 |
| ▸ | CCR3 | P51677 | 13/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.48 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3282974 | 1.00 | HRH1 (0.48) | HRH1CCR3KCNH2CNR2KDM4E | |
| SCHEMBL3283132 | 0.90 | HRH1 (0.50) | HRH1CCR3KCNH2CNR2 | |
| SCHEMBL3283140 | 0.90 | HRH1 (0.50) | HRH1CCR3KCNH2CNR2 | |
| SCHEMBL3286028 | 0.89 | HRH1 (0.46) | HRH1CCR3KCNH2CNR2ALDH1A1 | |
| SCHEMBL3286021 | 0.89 | HRH1 (0.46) | HRH1CCR3KCNH2CNR2ALDH1A1 | |
| SCHEMBL6648874 | 0.83 | HRH1 (0.54) | HRH1CCR3KCNH2CYP1A2CYP2D6 | |
| SCHEMBL1929697 | 0.83 | HRH1 (0.54) | HRH1CCR3KCNH2CYP1A2CYP2D6 | |
| SCHEMBL929709 | 0.80 | ABL1 (0.50) | CNR2 | |
| SCHEMBL3283342 | 0.78 | MAPT (0.45) | HRH1CCR3ALDH1A1 | |
| SCHEMBL13324620 | 0.77 | HRH1 (0.71) | HRH1CCR3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7709500-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2010-05-04 | — | — | US | disclosed |
| US-7709500-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2010-05-04 | — | — | US | disclosed |
| US-7709500-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2010-05-04 | — | — | US | disclosed |
| US-20050107428-A1 | Chemical compounds | ASTRAZENECA AB (SE) | 2005-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107428-A1 | Chemical compounds | CCR10, CCR3, CXCR5 | HRH1 33/4885CCR3 2/4885KCNH2 862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.